{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:51:28Z","timestamp":1781106688696,"version":"3.54.1"},"reference-count":49,"publisher":"National Academy of Sciences","issue":"29","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"vor","delay-in-days":184,"URL":"http:\/\/www.pnas.org\/site\/aboutpnas\/licenses.xhtml"}],"funder":[{"name":"Immunotherapy Foundation","award":["None"],"award-info":[{"award-number":["None"]}]},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","award":["2015"],"award-info":[{"award-number":["2015"]}],"id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2018,7,17]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>\n                    A major goal of cancer immunotherapy is the expansion and\/or reactivation of cytotoxic CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell responses against malignant cells. We previously showed that the direct injection of toll-like receptor 7 (TLR7) agonists into primary tumors can induce tumor-specific oligoclonal T cell responses whose magnitude correlates with therapeutic efficacy. However, tumors are not always accessible to local therapy. Here, we demonstrate in murine lung metastasis models that single systemic administration of a phospholipid conjugated TLR7 agonist can also expand tumor-specific cytotoxic T cells that are shared by different animals. The expansion can be achieved without causing apparent toxicity. Similar technology combining immune repertoire analysis and immunomodulatory drugs can help to guide the development of optimal immunotherapeutic regimens in cancer patients.\n                  <\/jats:p>","DOI":"10.1073\/pnas.1803281115","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T15:12:46Z","timestamp":1530544366000},"update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":27,"title":["Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist"],"prefix":"10.1073","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-6413","authenticated-orcid":false,"given":"Tadashi","family":"Hosoya","sequence":"first","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0695;"},{"name":"Graduate School of Tokyo Medical and Dental University, 113-8519, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Sato-Kaneko","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0695;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alast","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0695;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyin","family":"Yao","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0695;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitzgerald","family":"Lao","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0695;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Kitaura","sequence":"additional","affiliation":[{"name":"Repertoire Genesis Inc., Ibaraki-shi, 567-0085 Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaji","family":"Matsutani","sequence":"additional","affiliation":[{"name":"Repertoire Genesis Inc., Ibaraki-shi, 567-0085 Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Carson","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0695;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-8348","authenticated-orcid":false,"given":"Tomoko","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0695;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2018,7,2]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc.2016.25","article-title":"Targeting metastasis","volume":"16","author":"Steeg PS","year":"2016","unstructured":"PS Steeg, Targeting metastasis. Nat Rev Cancer 16, 201\u2013218 (2016).","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging biological principles of metastasis","volume":"168","author":"Lambert AW","year":"2017","unstructured":"AW Lambert, DR Pattabiraman, RA Weinberg, Emerging biological principles of metastasis. Cell 168, 670\u2013691 (2017).","journal-title":"Cell"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.1097\/RTI.0b013e3182010bf9","article-title":"ACR Appropriateness Criteria\u00ae screening for pulmonary metastases","volume":"26","author":"Mohammed T-LH","year":"2011","unstructured":"T-LH Mohammed, , ACR Appropriateness Criteria\u00ae screening for pulmonary metastases. J Thorac Imaging; Expert Panel on Thoracic Imaging 26, W1\u2013W3 (2011).","journal-title":"J Thorac Imaging"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura T","year":"2015","unstructured":"T Kitamura, BZ Qian, JW Pollard, Immune cell promotion of metastasis. Nat Rev Immunol 15, 73\u201386 (2015).","journal-title":"Nat Rev Immunol"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4049\/jimmunol.1701019","article-title":"Myeloid-derived suppressor cells: Immune-suppressive cells that impair antitumor immunity and are sculpted by their environment","volume":"200","author":"Ostrand-Rosenberg S","year":"2018","unstructured":"S Ostrand-Rosenberg, C Fenselau, Myeloid-derived suppressor cells: Immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. J Immunol 200, 422\u2013431 (2018).","journal-title":"J Immunol"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential","volume":"161","author":"Sharma P","year":"2015","unstructured":"P Sharma, JP Allison, Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).","journal-title":"Cell"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok JD","year":"2013","unstructured":"JD Wolchok, , Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369, 122\u2013133 (2013).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer J","year":"2015","unstructured":"J Brahmer, , Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373, 123\u2013135 (2015).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok JD","year":"2017","unstructured":"JD Wolchok, , Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377, 1345\u20131356 (2017).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies","volume":"50","author":"Geisse J","year":"2004","unstructured":"J Geisse, , Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50, 722\u2013733 (2004).","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/bjc.1996.569","article-title":"A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily","volume":"74","author":"Savage P","year":"1996","unstructured":"P Savage, , A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer 74, 1482\u20131486 (1996).","journal-title":"Br J Cancer"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ecp.11.5","article-title":"The pharmacokinetics of toll-like receptor agonists and the impact on the immune system","volume":"4","author":"Engel AL","year":"2011","unstructured":"AL Engel, GE Holt, H Lu, The pharmacokinetics of toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol 4, 275\u2013289 (2011).","journal-title":"Expert Rev Clin Pharmacol"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1021\/bc900054q","article-title":"Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates","volume":"20","author":"Chan M","year":"2009","unstructured":"M Chan, , Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug Chem 20, 1194\u20131200 (2009).","journal-title":"Bioconjug Chem"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000355217","article-title":"Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand","volume":"6","author":"Wu CCN","year":"2014","unstructured":"CCN Wu, , Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand. J Innate Immun 6, 315\u2013324 (2014).","journal-title":"J Innate Immun"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/CMR.0b013e328340ce6c","article-title":"Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2","volume":"21","author":"Hayashi T","year":"2011","unstructured":"T Hayashi, , Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. Melanoma Res 21, 66\u201375 (2011).","journal-title":"Melanoma Res"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"93397","DOI":"10.1172\/jci.insight.93397","article-title":"Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer","volume":"2","author":"Sato-Kaneko F","year":"2017","unstructured":"F Sato-Kaneko, , Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight 2, 93397 (2017).","journal-title":"JCI Insight"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1158\/1535-7163.MCT-09-1198","article-title":"Antitumor activity and immune response induction of a dual agonist of toll-like receptors 7 and 8","volume":"9","author":"Wang D","year":"2010","unstructured":"D Wang, , Antitumor activity and immune response induction of a dual agonist of toll-like receptors 7 and 8. Mol Cancer Ther 9, 1788\u20131797 (2010).","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ijc.27691","article-title":"Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer","volume":"132","author":"Koga-Yamakawa E","year":"2013","unstructured":"E Koga-Yamakawa, , Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Int J Cancer 132, 580\u2013590 (2013).","journal-title":"Int J Cancer"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1172\/JCI36551","article-title":"Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance","volume":"120","author":"Cherfils-Vicini J","year":"2010","unstructured":"J Cherfils-Vicini, , Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 120, 1285\u20131297 (2010).","journal-title":"J Clin Invest"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1158\/0008-5472.CAN-13-2698","article-title":"TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer","volume":"74","author":"Chatterjee S","year":"2014","unstructured":"S Chatterjee, , TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer Res 74, 5008\u20135018 (2014).","journal-title":"Cancer Res"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1172\/JCI63606","article-title":"Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans","volume":"122","author":"Ochi A","year":"2012","unstructured":"A Ochi, , Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest 122, 4118\u20134129 (2012).","journal-title":"J Clin Invest"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"e991615","DOI":"10.4161\/2162402X.2014.991615","article-title":"Dual roles of TLR7 in the lung cancer microenvironment","volume":"4","author":"Dajon M","year":"2015","unstructured":"M Dajon, K Iribarren, I Cremer, Dual roles of TLR7 in the lung cancer microenvironment. Oncoimmunology 4, e991615 (2015).","journal-title":"Oncoimmunology"},{"key":"e_1_3_4_23_2","first-page":"Unit 20.2","article-title":"Mouse 4T1 breast tumor model","volume":"20","author":"Pulaski BA","year":"2001","unstructured":"BA Pulaski, S Ostrand-Rosenberg, Mouse 4T1 breast tumor model. Curr Protoc Immunol Chapter 20, Unit 20.2 (2001).","journal-title":"Curr Protoc Immunol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.3892\/or.2017.5536","article-title":"Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer","volume":"37","author":"Ikeda Y","year":"2017","unstructured":"Y Ikeda, , Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer. Oncol Rep 37, 2603\u20132610 (2017).","journal-title":"Oncol Rep"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi SK","year":"2016","unstructured":"SK Subudhi, , Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci USA 113, 11919\u201311924 (2016).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"8785","DOI":"10.1073\/pnas.95.15.8785","article-title":"Activation of preexisting T cell clones by targeted interleukin 2 therapy","volume":"95","author":"Straten PT","year":"1998","unstructured":"PT Straten, , Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci USA 95, 8785\u20138790 (1998).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.surg.2004.05.003","article-title":"CDR3 spectratyping identifies clonal expansion within T-cell subpopulations that demonstrate therapeutic antitumor activity","volume":"136","author":"Kim JA","year":"2004","unstructured":"JA Kim, , CDR3 spectratyping identifies clonal expansion within T-cell subpopulations that demonstrate therapeutic antitumor activity. Surgery 136, 295\u2013302 (2004).","journal-title":"Surgery"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-0236","article-title":"Expansion of tumor-infiltrating CD8+T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy","volume":"77","author":"Fernandez-Poma SM","year":"2017","unstructured":"SM Fernandez-Poma, , Expansion of tumor-infiltrating CD8+T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy. Cancer Res 77, 3672\u20133684 (2017).","journal-title":"Cancer Res"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s002510000248","article-title":"A new method for quantitative analysis of the mouse T-cell receptor V region repertoires: Comparison of repertoires among strains","volume":"52","author":"Yoshida R","year":"2000","unstructured":"R Yoshida, , A new method for quantitative analysis of the mouse T-cell receptor V region repertoires: Comparison of repertoires among strains. Immunogenetics 52, 35\u201345 (2000).","journal-title":"Immunogenetics"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12859-017-1544-9","article-title":"3D: Diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data","volume":"18","author":"Zhang L","year":"2017","unstructured":"L Zhang, , 3D: Diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data. BMC Bioinformatics 18, 129 (2017).","journal-title":"BMC Bioinformatics"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1128\/JVI.03337-14","article-title":"Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses","volume":"89","author":"Goff PH","year":"2015","unstructured":"PH Goff, , Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol 89, 3221\u20133235 (2015).","journal-title":"J Virol"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12967-014-0275-1","article-title":"PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche","volume":"12","author":"Godebu E","year":"2014","unstructured":"E Godebu, , PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. J Transl Med 12, 275 (2014).","journal-title":"J Transl Med"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood-2006-09-046201","article-title":"Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host","volume":"109","author":"Liu C","year":"2007","unstructured":"C Liu, , Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109, 4336\u20134342 (2007).","journal-title":"Blood"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.4049\/jimmunol.175.3.1636","article-title":"TLR7\/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production","volume":"175","author":"Hart OM","year":"2005","unstructured":"OM Hart, V Athie-Morales, GM O\u2019Connor, CM Gardiner, TLR7\/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 175, 1636\u20131642 (2005).","journal-title":"J Immunol"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/eji.1830100304","article-title":"A glycolipid on the surface of mouse natural killer cells","volume":"10","author":"Kasai M","year":"1980","unstructured":"M Kasai, M Iwamori, Y Nagai, K Okumura, T Tada, A glycolipid on the surface of mouse natural killer cells. Eur J Immunol 10, 175\u2013180 (1980).","journal-title":"Eur J Immunol"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1152\/ajpregu.00527.2007","article-title":"Mast cell-dependent anorexia and hypothermia induced by mucosal activation of toll-like receptor 7","volume":"295","author":"Hayashi T","year":"2008","unstructured":"T Hayashi, , Mast cell-dependent anorexia and hypothermia induced by mucosal activation of toll-like receptor 7. Am J Physiol Regul Integr Comp Physiol 295, R123\u2013R132 (2008).","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s10875-012-9687-y","article-title":"Therapy with TLR7 agonists induces lymphopenia: Correlating pharmacology to mechanism in a mouse model","volume":"32","author":"Perkins H","year":"2012","unstructured":"H Perkins, , Therapy with TLR7 agonists induces lymphopenia: Correlating pharmacology to mechanism in a mouse model. J Clin Immunol 32, 1082\u20131092 (2012).","journal-title":"J Clin Immunol"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: Molecular insights and evolving paradigms","volume":"147","author":"Valastyan S","year":"2011","unstructured":"S Valastyan, RA Weinberg, Tumor metastasis: Molecular insights and evolving paradigms. Cell 147, 275\u2013292 (2011).","journal-title":"Cell"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian SL","year":"2016","unstructured":"SL Topalian, JM Taube, RA Anders, DM Pardoll, Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16, 275\u2013287 (2016).","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer MH","year":"2017","unstructured":"MH Spitzer, , Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487\u2013502.e15 (2017).","journal-title":"Cell"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri2260","article-title":"The molecular basis for public T-cell responses?","volume":"8","author":"Venturi V","year":"2008","unstructured":"V Venturi, DA Price, DC Douek, MP Davenport, The molecular basis for public T-cell responses? Nat Rev Immunol 8, 231\u2013238 (2008).","journal-title":"Nat Rev Immunol"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.175.9.6123","article-title":"Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses","volume":"175","author":"Trautmann L","year":"2005","unstructured":"L Trautmann, , Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J Immunol 175, 6123\u20136132 (2005).","journal-title":"J Immunol"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1038\/s41598-017-03855-x","article-title":"Highly functional T-cell receptor repertoires are abundant in stem memory T cells and highly shared among individuals","volume":"7","author":"Miyama T","year":"2017","unstructured":"T Miyama, , Highly functional T-cell receptor repertoires are abundant in stem memory T cells and highly shared among individuals. Sci Rep 7, 3663 (2017).","journal-title":"Sci Rep"},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.4049\/jimmunol.168.10.4907","article-title":"IFN-alpha beta promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines","volume":"168","author":"Cho HJ","year":"2002","unstructured":"HJ Cho, , IFN-alpha beta promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol 168, 4907\u20134913 (2002).","journal-title":"J Immunol"},{"key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4049\/jimmunol.175.2.1197","article-title":"Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK","volume":"175","author":"Hagemann T","year":"2005","unstructured":"T Hagemann, , Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175, 1197\u20131205 (2005).","journal-title":"J Immunol"},{"key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.bbadis.2017.01.006","article-title":"IL-6 promotes M2 macrophage polarization by modulating purinergic signaling and regulates the lethal release of nitric oxide during Trypanosoma cruzi infection","volume":"1863","author":"Sanmarco LM","year":"2017","unstructured":"LM Sanmarco, , IL-6 promotes M2 macrophage polarization by modulating purinergic signaling and regulates the lethal release of nitric oxide during Trypanosoma cruzi infection. Biochim Biophys Acta 1863, 857\u2013869 (2017).","journal-title":"Biochim Biophys Acta"},{"key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail DF","year":"2013","unstructured":"DF Quail, JA Joyce, Microenvironmental regulation of tumor progression and metastasis. Nat Med 19, 1423\u20131437 (2013).","journal-title":"Nat Med"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1634\/theoncologist.2008-0097","article-title":"The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy","volume":"13","author":"Smits ELJM","year":"2008","unstructured":"ELJM Smits, P Ponsaerts, ZN Berneman, VFI Van Tendeloo, The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13, 859\u2013875 (2008).","journal-title":"Oncologist"},{"key":"e_1_3_4_49_2","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council","year":"2011","unstructured":"; National Research Council Guide for the Care and Use of Laboratory Animals (National Academies Press, 8th Ed, Washington, DC, 2011).","edition":"8"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1803281115","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1803281115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T13:33:45Z","timestamp":1654608825000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1803281115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,2]]},"references-count":49,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,7,17]]}},"alternative-id":["10.1073\/pnas.1803281115"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1803281115","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,2]]},"assertion":[{"value":"2018-07-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}